RETRACTION NOTE

Open Access



Retraction Note: Combined treatment of glibenclamide and CoCl₂ decreases MMP9 expression and inhibits growth in highly metastatic breast cancer

Zhe Rong^{1*}, Li Li², Fei Fei², Lailong Luo² and Yang Qu³

Retraction Note: J Exp Clin Cancer Res32, 32 (2013) https://doi.org/10.1186/1756-9966-32-32

The Editor-in-Chief has retracted this article. After publication, concerns were raised regarding high similarity among the MMP-9 DMSO, Gibenclamide, and Paclitaxel images in Fig. 2B.

Due to the severity of these concerns in the context of the article, the Editor-in-Chief no longer has confidence in the presented data.

None of the authors have responded to any correspondence from the Publisher about this retraction.
Published online: 04 February 2025

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/1756-9966-32-32.

*Correspondence:

Zhe Rong

mingzhe23@aliyun.com

¹Department of Basic Medicine & Experimental Technology, Division of Clinical Medicine, Logistic University of Chinese People's Armed Police Force, Tianiin 300162. P. R. China

²Department of Pathology, Anhui Medical University, Hefei 230032, Anhui Province, P. R. China

³Department of Neurosurgery, Logistic University Affiliated Hospital, Logistic University of Chinese People's Armed Police Force, Tianjin 300162, P. R. China



© BioMed Central_BMCE 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material, if material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.